vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and NEW JERSEY RESOURCES CORP (NJR). Click either name above to swap in a different company.
NEW JERSEY RESOURCES CORP is the larger business by last-quarter revenue ($939.4M vs $281.3M, roughly 3.3× Guardant Health, Inc.). NEW JERSEY RESOURCES CORP runs the higher net margin — 23.3% vs -45.7%, a 69.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -33.0%). Over the past eight quarters, NEW JERSEY RESOURCES CORP's revenue compounded faster (111.6% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
New Jersey Resources is an energy services holding company based in Wall Township, New Jersey. It is a Fortune 1000 company, and a member of the Forbes Platinum 400. New Jersey Natural Gas is its principal subsidiary.
GH vs NJR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $939.4M |
| Net Profit | $-128.5M | $218.9M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 32.0% |
| Net Margin | -45.7% | 23.3% |
| Revenue YoY | 39.4% | -33.0% |
| Net Profit YoY | -15.8% | 7.2% |
| EPS (diluted) | $-1.01 | $2.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $939.4M | ||
| Q4 25 | $281.3M | $440.9M | ||
| Q3 25 | $265.2M | $188.3M | ||
| Q2 25 | $232.1M | $234.8M | ||
| Q1 25 | $203.5M | $569.2M | ||
| Q4 24 | $201.8M | $359.0M | ||
| Q3 24 | $191.5M | $265.7M | ||
| Q2 24 | $177.2M | $209.9M |
| Q1 26 | — | $218.9M | ||
| Q4 25 | $-128.5M | $122.5M | ||
| Q3 25 | $-92.7M | $15.1M | ||
| Q2 25 | $-99.9M | $-15.1M | ||
| Q1 25 | $-95.2M | $204.3M | ||
| Q4 24 | $-111.0M | $131.3M | ||
| Q3 24 | $-107.8M | $91.1M | ||
| Q2 24 | $-102.6M | $-11.6M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | 32.0% | ||
| Q4 25 | -43.0% | 40.6% | ||
| Q3 25 | -37.3% | 21.5% | ||
| Q2 25 | -45.9% | -0.5% | ||
| Q1 25 | -54.6% | 49.2% | ||
| Q4 24 | -62.4% | 52.8% | ||
| Q3 24 | -61.3% | 55.0% | ||
| Q2 24 | -56.8% | 2.8% |
| Q1 26 | — | 23.3% | ||
| Q4 25 | -45.7% | 27.8% | ||
| Q3 25 | -35.0% | 8.0% | ||
| Q2 25 | -43.0% | -6.4% | ||
| Q1 25 | -46.8% | 35.9% | ||
| Q4 24 | -55.0% | 36.6% | ||
| Q3 24 | -56.3% | 34.3% | ||
| Q2 24 | -57.9% | -5.5% |
| Q1 26 | — | $2.16 | ||
| Q4 25 | $-1.01 | $1.21 | ||
| Q3 25 | $-0.74 | $0.15 | ||
| Q2 25 | $-0.80 | $-0.15 | ||
| Q1 25 | $-0.77 | $2.02 | ||
| Q4 24 | $-0.90 | $1.31 | ||
| Q3 24 | $-0.88 | $0.91 | ||
| Q2 24 | $-0.84 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | — |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | — |
| Total Assets | $2.0B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $378.2M | $2.4M | ||
| Q3 25 | $580.0M | $591.0K | ||
| Q2 25 | $629.1M | $931.0K | ||
| Q1 25 | $698.6M | $83.7M | ||
| Q4 24 | $525.5M | $1.9M | ||
| Q3 24 | $585.0M | $1.0M | ||
| Q2 24 | $933.7M | $22.4M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $3.3B | ||
| Q3 25 | $1.1B | $3.3B | ||
| Q2 25 | $1.1B | $3.0B | ||
| Q1 25 | $1.1B | $3.0B | ||
| Q4 24 | $1.1B | $3.0B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | $-99.3M | $2.5B | ||
| Q3 25 | $-354.5M | $2.4B | ||
| Q2 25 | $-305.5M | $2.4B | ||
| Q1 25 | $-250.8M | $2.5B | ||
| Q4 24 | $-139.6M | $2.3B | ||
| Q3 24 | $-60.1M | $2.2B | ||
| Q2 24 | $-1.6M | $2.1B |
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $7.9B | ||
| Q3 25 | $1.3B | $7.6B | ||
| Q2 25 | $1.3B | $7.3B | ||
| Q1 25 | $1.3B | $7.3B | ||
| Q4 24 | $1.5B | $7.2B | ||
| Q3 24 | $1.5B | $7.0B | ||
| Q2 24 | $1.6B | $6.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.32× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | 1.30× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $26.7M | ||
| Q3 25 | $-35.4M | $81.2M | ||
| Q2 25 | $-60.3M | $-28.9M | ||
| Q1 25 | $-62.7M | $423.0M | ||
| Q4 24 | $-64.5M | $-9.0M | ||
| Q3 24 | $-51.1M | $64.5M | ||
| Q2 24 | $-94.0M | $24.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 5.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.07× | ||
| Q4 24 | — | -0.07× | ||
| Q3 24 | — | 0.71× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
NJR
| Utility | $640.9M | 68% |
| Nonutility | $298.5M | 32% |
